Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2019-001623-12-IT
EUCTR2019-001623-12-ITActive, not recruitingPhase 1

RANDOMIZED PHASE III MULTICENTRE STUDY INVESTIGATING THE ROLE OF LETROZOLE IN HEAVILY PRETREATED RECURRENT OVARIAN CANCER - MITO 32

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 sites236 target enrollmentStarted: June 17, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
236
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Female

Inclusion Criteria

  • •Female of 18 years of age or older
  • •Histologically or cytologically documented invasive epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
  • •Platinum resistant or refractory disease (patients who did not respond to last platinum-based therapy or with last relapse occurred < 6 months from the last dose of platinum) or patients not amenable of platinum treatment
  • •>3 previous chemotherapy lines
  • •ECOG performance status 0 -2
  • •Measurable and evaluable disease according to RECIST criteria confirmed by radiological imaging: at least one lesion of = 1.0 cm for non-lymph nodes or = 1.5 cm in short-axis diameter for lymph nodes at CT scan (Subjects with isolated rising CA-125 without radiologically visible disease are excluded)
  • •Left Ventricular Ejection Fraction (LVEF) = institutional lower limit normal
  • •Estimated life expectancy = 16 weeks
  • •Adequate functions evidenced by:
  • •¬Hemoglobin 10.0 g/dl
  • •¬Absolute neutrophil count 1.5 x 109/L
  • •¬White blood cells >3x109/L
  • •¬Platelet >100 x109/L
  • •¬AST and ALT 2.5 x Upper limit of normal, unless liver metastasis
  • •¬Bilirubin = 1.5 times the upper limit of normal (ULN)
  • •Estimated glomerular filtration 60mL/min
  • •Patient able to comply with the treatment
  • •Evidence of not pregnancy status as documented by a negative beta-human chorionic gonadotropin (ß-hCG) test
  • •Not breastfeeding women
  • •Patients with child-bearing potential using (or willing to use) effective contraception during treatment and 3 months ahead unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically
  • •Comprehension and signature of the informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 180
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 56

Exclusion Criteria

  • •Subjects with borderline ovarian cancer
  • •Subject with low malignant potential tumors
  • •Less than 3 lines of previous therapies
  • •Platinum sensitive disease (last relapse occurred > 6 months from the last dose of platinum)
  • •Less than 4 weeks from last dose of therapy with any investigational agent, or chemotherapy
  • •History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for 3 years or longer
  • •Breastfeeding women
  • •Pregnant women
  • •Prior therapy with letrozole
  • •Severe osteoporosis documented by Bone Mineral Density(BMD) T-score = -2.5 with existing fragility fracture(s)
  • •Patients with a known hypersensitivity to Paclitaxel , PLD, Topotecan, Gemcitabine or Letrozole or any case of severe toxicity related to them.
  • •Prior resistance to Paclitaxel , PLD, Topotecan, Gemcitabine
  • •Patients with active hepatic disease (HCV or HBV infections), hepatic severe impairment or cirrhosis
  • •Bowel obstruction, sub-occlusive disease, prior gastrectomy, symptomatic brain metastases
  • •Myocardial infarct within six months before enrolment , NYHA Class II or worse heart failure, unstable angina, serious cardiac arrhythmia or cardiac arrhythmia requiring treatment
  • •Any serious concomitant illness requiring treatment
  • •Pre-existing peripheral neuropathy > CTCAE Grade 2
  • •Concomitant use of strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, and telithromycin) or strong CYP2A6 inhibitors (e.g. methoxsalen) because they may increase exposure to letrozole
  • •Concomitant use of inducers of CYP3A4 (e.g. phenytoin, rifampicin, carbamazepine, phenobarbital, and St. John’s Wort) which may reduce exposure to letrozole
  • •Concomitant use of medicinal products with a narrow therapeutic index that are substrates for CYP2C19 (e.g. phenytoin, clopidrogel) that may have their systemic serum concentrations altered by letrozole

Investigators

Sponsor
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE

Similar Trials

Completed
Not Applicable
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
PER-055-04BRISTOL MYERS SQUIBB COMPANY,
Completed
Not Applicable
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50
PER-045-04GLAXOSMITHKLINE PERU S.A.,40
Active, not recruiting
Phase 1
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical CystectomyMuscle-Invasive Urothelial Carcinoma (MIBC) of the BladderMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10046720Term: Urothelial carcinoma bladder stage IISystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10046721Term: Urothelial carcinoma bladder stage IIISystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10046722Term: Urothelial carcinoma bladder stage IVSystem Organ Class: 100000004864
EUCTR2020-002620-36-PTJanssen-Cilag International NV550
Active, not recruiting
Phase 1
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical CystectomyMuscle-Invasive Urothelial Carcinoma (MIBC) of the BladderMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10046720Term: Urothelial carcinoma bladder stage IISystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10046721Term: Urothelial carcinoma bladder stage IIISystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10046722Term: Urothelial carcinoma bladder stage IVSystem Organ Class: 100000004864
EUCTR2020-002620-36-ITJANSSEN CILAG INTERNATIONAL NV550
Active, not recruiting
Phase 1
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy
EUCTR2020-002620-36-CZJanssen-Cilag International NV550